Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Soleno Therapeutics, Inc. - Common Stock (NQ:SLNO)

67.66 -3.79 (-5.30%)
Streaming Delayed Price Updated: 2:05 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Soleno Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Tesla To $455? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Soleno Shares Are Up Today: What's Going On?
Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares are trading higher Thursday after the company announced it secured FDA approval for its first commercial drug, Vykat XR (diazoxide choline)... 
Via Benzinga
Exposures Product Safety
Top stock movements in today's session.
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Soleno Therapeutics Stock Is Skyrocketing Today
The clinical-stage biotech company received great news from the FDA. 
Via The Motley Fool
Which stocks are gapping on Thursday?
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results
Via Benzinga
Top movers in Thursday's pre-market session
Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, Pulling Aardvark Higher
The drug treats excessive hunger that often leads to obesity in patients with a rare, genetic disease. 
Via Investor's Business Daily
Behind the Scenes of Soleno Therapeutics's Latest Options Trends
Via Benzinga
Soleno Therapeutics Stock Rockets 34% Pre-Market After FDA Approves Prader-Willi Syndrome Drug: Retail Sentiment Peaks
The company expects the drug, the first approved therapy to address hyperphagia in PWS patients, to be available in the U.S. starting April 2025. 
Via Stocktwits
Exposures Product Safety
Soleno Therapeutics Secures FDA Approval For Its First Commercial Drug For Rare Genetic Disorder
Soleno's Vykat XR wins FDA approval as the first treatment for hyperphagia in Prader-Willi syndrome, with U.S. availability expected by April 2025. 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
US Stocks Likely To Open Mixed: 'Expect Volatility. Buckle Up,' Says Expert
U.S. stock futures were swinging between gains and losses on Thursday after snapping a three-day winning streak on Wednesday. Futures of major benchmark indices were mixed in premarket trading. Aiming... 
Via Benzinga
Topics Supply Chain World Trade
Exposures Supply Chain Tariff
Why Greenland Technologies Shares Are Trading Higher By Around 89%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Soleno Therapeutics Stock Blasted 9% Higher Today
The company's Prader-Willi treatment inched closer to FDA approval. 
Via The Motley Fool
Exposures Product Safety
PepsiCo, DocuSign, Robinhood And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Hain Celestial Posts Upbeat Q4 Earnings, Joins Soleno Therapeutics, Energizer Holdings And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
SLNO Stock Earnings: Soleno Therapeutics Beats EPS for Q2 2024
SLNO stock results show that Soleno Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Nvidia Is Up 186% From A Year Ago, Yet These 7 Stocks Have More Than Doubled Their Returns Over The AI Chipmaker
NVIDIA Corp. (NASDAQ:NVDA) has been the standout tech stock of the past year, leading the Nasdaq 100 index in the performance ranking. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
SLNO Stock Earnings: Soleno Therapeutics Misses EPS for Q1 2024
SLNO stock results show that Soleno Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
US Stocks Kick Off The Week In The Green, Tesla Rockets On China's FSD Approval, Yen Rallies: What's Driving Markets Monday?
U.S. stocks kicked off the week on a positive note, with all major averages edging higher in anticipation of significant events including earnings reports from tech giants like Amazon.com Inc.... 
Via Benzinga
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday
Via Benzinga
SLNO Stock Earnings: Soleno Therapeutics Misses EPS for Q4 2023
SLNO stock results show that Soleno Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Forget The Magnificent 7: Did Anyone Back These 1,000% Gainers In 2023?
Baron Fifth Avenue Growth Fund gained nearly 60% over the year, while the Fidelity Blue Chip Growth ETF climbed 59%. 
Via Benzinga
Topics ETFs
These Two Companies Surpass Nvidia, Apple And Microsoft with Astounding 1000% Returns In 2023
The two companies outperformed the 'Magnificent Seven' group of stocks, which includes tech giants such as Nvidia, Apple, and Microsoft. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.